Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.
Metastatic Thyroid Papillary Carcinoma|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Cancer
DRUG: Durvalumab|DRUG: Tremelimumab
Progression-free survival rate at 6 months, Percentage of patients without progression of disease at month 6, according RECIST 1.1 criteria., 6 months|Overall survival rate at 6 months, Percentage of patients alive at month 6 from first dose of treatment., 6 months
Overall response rate (ORR), Response to treatment according to RECIST 1.1 criteria or iRECIST 1.1 criteria, 42 months|Duration of response (DoR), Length of time between start of treatment and date of evidenced response and progression of disease according irRECIST or RECIST 1.1 criteria, or death, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months|Median progression-free survival, Length of time between date of evidenced response and progression of disease according irRECIST or RECIST 1.1 criteria, or death, or death, 42 months|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Number and type of adverse events reported throughout the study period, 42 months|Median Overall Survival, Length of time between start of treatment and death, 42 months|Response status after start of study treatment, According irRECIST/RECIST, 6 and 12 months after start of the study treatment
This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.